Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218530 · ClinicalTrials.gov registry record · Phase 1
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
A Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00218530: Completed Phase 1 study, sponsored by National Institute on Drug Abuse (NIDA).
NCT00218530 is a Phase 1 study that has completed, run by National Institute on Drug Abuse (NIDA). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218530, a Phase 1 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
Stress is one of the more common reasons cited by addicts for continual drug use and relapse. Treatment approaches that target both drug-induced and stress-induced relapse may prove to be more beneficial than targeting drug-induced relapse alone. Lofexidine is a drug that reduces the physical symptoms of opiate withdrawal and may prove to have stress-reducing capabilites in drug addicts. The purpose of this study is to determine the maximal safe dose of lofexidine tolerated in naltrexone-treated heroin addicts and to find an optimal lofexidine induction schedule.
Interventions
- DRUG Lofexidine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-03 |
| Est. Completion | 2004-09 |
| Phase | Phase 1 |
What the finished NCT00218530 record still lists
NCT00218530 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Lofexidine is the first listed.
NCT00218530 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00218530 about?
NCT00218530 is a clinical study titled "Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1". Stress is one of the more common reasons cited by addicts for continual drug use and relapse. Treatment approaches that target both drug-induced and stress-induced relapse may prove to be more beneficial than targeting drug-induced relapse alone. Lofexidine is a drug that reduces the physical sympto...
What is the current status of trial NCT00218530?
This trial is currently completed. It is a Phase 1 study. The study started on 2003-03. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00218530?
The interventions under investigation include: Lofexidine (DRUG).
Who is sponsoring clinical trial NCT00218530?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia